Hct Puren

Hct Puren is a pharmaceutical product that contains the thiazide diuretic hydrochlorothiazide as its active ingredient. It is marketed in the European Union and is supplied for oral administration. While the specific strength and dosage form are not listed, the medication belongs to the antihypertensive and diuretic therapeutic classes and is identified by the ATC code C03AA03. It is typically prescribed for high blood pressure.

Hct Puren, containing hydrochlorothiazide, is used in clinical practice for several cardiovascular and renal indications.

- Management of essential hypertension, helping to lower elevated systolic and diastolic blood pressure. - Reduction of peripheral edema related to congestive heart failure, by promoting fluid excretion. - Treatment of ascites‑related fluid accumulation in patients with liver cirrhosis. - Control of edema associated with chronic kidney disease or nephrotic syndrome. - Adjunctive therapy combined with other antihypertensive agents when monotherapy is insufficient. - Use in combination with potassium‑sparing diuretics to mitigate potassium loss in selected patients.

The safety profile of Hct Puren reflects the typical effects observed with thiazide diuretics, ranging from mild, frequently reported events to rare but serious reactions.

Common: - Increased frequency of urination caused by enhanced diuresis, typically noticeable within the first few doses. - Mild electrolyte disturbances, most often low serum potassium (hypokalemia) or sodium (hyponatremia), which may be detected on routine labs. - Transient dizziness or light‑headedness, especially when standing quickly after taking the medication. - Slight elevation of fasting blood glucose levels in patients with pre‑existing glucose intolerance.

Serious: - Severe dehydration or marked electrolyte imbalance that can lead to symptomatic hypotension and fainting. - Acute allergic reactions such as rash, pruritus, or angioedema, and rare cases of acute kidney injury indicated by a rapid rise in serum creatinine.

When prescribing Hct Puren, clinicians consider several precautionary measures to ensure safe and effective use.

- Assess baseline blood pressure and renal function before initiating therapy. - Monitor electrolytes, especially potassium and sodium, during treatment and after dose adjustments. - Use caution in patients with a history of gout, as thiazides may increase uric acid levels. - Adjust dose or discontinue if significant hypotension or dehydration occurs. - Evaluate for diabetes mellitus, since thiazide diuretics can modestly raise blood glucose. - Avoid use in patients with known hypersensitivity to hydrochlorothiazide or other sulfonamide drugs.

Hydrochlorothiazide may interact with several medicines, influencing its diuretic effect or increasing the risk of adverse events.

Avoid: - Lithium, because thiazides can raise serum lithium concentrations and precipitate toxicity. - Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may blunt the diuretic response and impair renal function. - Cyclosporine, as combined use can enhance nephrotoxic risk.

Use with caution: - Antihypertensive agents such as ACE inhibitors, ARBs, or beta‑blockers, where additive blood pressure lowering may cause hypotension. - Antidiabetic drugs, because thiazides can increase blood glucose and may require dose adjustment. - Corticosteroids, which can potentiate potassium loss and exacerbate electrolyte disturbances.